RxDoctor Payments Data

Jason Hand, MD

Internal Medicine · Saint Louis, MONPI 1083631519

Payments from drug & device makers

$227in general payments, 2019–2025

Across 16 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$41
  • Sanofi-aventis U.S. LLC$33
  • Johnson & Johnson$30
  • Astellas Pharma US Inc$29
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$27
  • AstraZeneca$26
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$227100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$227 in reported general payments places this provider in the 50th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$146,553
Medicare patients
321
Services billed
3,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$167,726
MounjaroTirzepatide90$103,806
OzempicSemaglutide82$94,088
XareltoRivaroxaban70$57,603
RybelsusSemaglutide20$48,186
JardianceEmpagliflozin34$41,389
TrulicityDulaglutide21$32,733
ArexvyRsvpref3 Antigen/As01e/Pf122$30,185
JanuviaSitagliptin Phosphate22$24,928
FarxigaDapagliflozin Propanediol18$23,439
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$22,247
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$11,533
Spiriva HandihalerTiotropium Bromide15$10,538
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$9,792
Advair HfaFluticasone Propion/Salmeterol23$9,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$30$57,60370 claims
AstraZenecaFarxiga, Symbicort$26$26,69832 claims
MerckJanuvia$41$24,92822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →